Hospitals awaiting regulator's guidance over Ranbaxy drugs
- LIVE: Yogendra Yadav, Prashant Bhushan expelled from AAP National Executive committee
- President Pranab Mukherjee goes to Vajpayee's home with Bharat Ratna
- Land bill will ‘break nation’s backbone’, Sonia tells Gadkari
- After 2010 scare, DGCA got cockpit policy to avert Germanwings-type incident
- Leave IITs alone, can’t talk to 36 applicants in a day and choose (directors): Kakodkar
Leading hospitals in Mumbai are awaiting guidance from the regulator Food and Drug Administration before taking any decision on issuing advisory over prescribing drugs manufactured by Ranbaxy.
"FDA is the regulatory authority here and unless it tells us, we will not do anything ... (issue advisory) over prescribing Ranbaxy drugs," Hinduja Hospital Director
Professional Services Dr Gustad Daver said.
Earlier, Jaslok Hospital in Mumbai had issued an advisory to its doctors to avoid prescribing drugs manufactured by Ranbaxy.
Apollo Pharmacy, India's largest pharmacy chain, has also issued 'cautionary' advisory based on concerns raised by the medical committee last week.
Leading hospitals in Mumbai like Kokilaben Hospital, KEM Hospital, Nanavati and Bombay Hospital have continued to prescribe the Ranbaxy drugs.
On May 13, Ranbaxy was asked to pay USD 500 million to settle the US government charges of selling adulterated drugs manufactured at its two plants in India.
The Indian Medical Association has asked the Drug Controller General of India to investigate the quality of drugs manufactured and sold by Ranbaxy.
Ranbaxy Laboratories is an integrated international pharmaceuticals company engaged in the marketing, production and distribution of pharmaceuticals products.
It manufactures medicines for cardiovascular, respiratory and gastro-intestinal ailments, besides anti-retroviral drugs.